Mleczko Mateusz, Kowalska-Kępczyńska Anna, Gerkowicz Agnieszka, Kowal Małgorzata, Krasowska Dorota
Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, 20-059 Lublin, Poland.
Department of Biochemical Diagnostics, Medical University of Lublin, 20-059 Lublin, Poland.
Biomedicines. 2025 Jul 3;13(7):1635. doi: 10.3390/biomedicines13071635.
Psoriasis is a chronic inflammatory skin disease frequently associated with systemic comorbidities. Human neutrophil peptides 1-3 (HNP1-3), released by neutrophils, have both antimicrobial and proinflammatory effects and may contribute to the pathogenesis of psoriasis and its related conditions. The aim of this study was to evaluate the serum levels of HNP1-3 in patients with psoriasis compared with healthy controls and to assess their association with selected comorbidities and clinical parameters. In this cross-sectional study, forty-nine patients with psoriasis and forty-nine matched healthy controls were enrolled. Serum HNP1-3 levels were measured using ELISA. Clinical data, including waist-to-hip ratio (WHR), smoking status, and the presence of comorbidities such as psoriatic arthritis (PsA), cardiovascular disease, and pulmonary or autoimmune disorders, were recorded. The mean HNP1-3 levels were significantly higher in the psoriasis patients than in the controls (3.85 ± 0.76 vs. 2.52 ± 0.84 ng/mL; < 0.001), especially in patients with concomitant PsA (4.21 ± 0.69 ng/mL). Multivariable regression identified increased WHR (β = 1.77, < 0.01) and smoking (β = 0.45, < 0.001) as independent predictors of elevated HNP1-3 levels. Positive correlations were also found between HNP1-3 and ESR (r = 0.505, = 0.019) and IL-6 (r = 0.561, = 0.008). The elevated serum HNP1-3 levels identified in psoriasis patients-especially those with PsA, central obesity, and smoking history-suggest their potential utility as biomarkers of systemic inflammation. These findings highlight the systemic nature of psoriasis and warrant further research into the clinical utility of HNP1-3 in disease monitoring and risk stratification.
银屑病是一种常伴有全身性合并症的慢性炎症性皮肤病。中性粒细胞释放的人中性粒细胞肽1 - 3（HNP1 - 3）具有抗菌和促炎作用，可能在银屑病及其相关病症的发病机制中起作用。本研究的目的是评估银屑病患者与健康对照者血清中HNP1 - 3的水平，并评估其与选定合并症和临床参数的关联。在这项横断面研究中，纳入了49例银屑病患者和49例匹配的健康对照者。使用酶联免疫吸附测定法（ELISA）测量血清HNP1 - 3水平。记录临床数据，包括腰臀比（WHR）、吸烟状况以及银屑病关节炎（PsA）、心血管疾病、肺部或自身免疫性疾病等合并症的存在情况。银屑病患者的HNP1 - 3平均水平显著高于对照组（3.85±0.76 vs. 2.52±0.84 ng/mL；<0.001），尤其是伴有PsA的患者（4.21±0.69 ng/mL）。多变量回归分析确定，腰臀比增加（β = 1.77，<0.01）和吸烟（β = 0.45，<0.001）是HNP1 - 3水平升高的独立预测因素。还发现HNP1 - 3与红细胞沉降率（ESR）（r = 0.505，P = 0.019）和白细胞介素 - 6（IL - 6）（r = 0.561，P = 0.008）呈正相关。银屑病患者中血清HNP1 - 3水平升高，尤其是那些患有PsA、中心性肥胖和有吸烟史的患者，表明它们作为全身炎症生物标志物的潜在效用。这些发现突出了银屑病的全身性本质，并值得进一步研究HNP1 - 3在疾病监测和风险分层中的临床效用。
